Ensysce Biosciences (Ensysce Biosciences) Growth Rank : 0 (As of Jun. 13, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Growth Rank?

Ensysce Biosciences has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Ensysce Biosciences Growth Rank Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensysce Biosciences (Ensysce Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037

Website

https://www.ensysce.com

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.

Executives

Bob G Gower	director	402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick	director, officer: Chief Executive Officer	110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman	officer: Chief Medical Officer	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch	director	C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano	officer: Chief Development Officer	7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett	officer: Chief Commercial Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt	officer: Chief Medical Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey	officer: Chief Financial Officer	4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang	director, 10 percent owner	C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard	officer: Chief Operating Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright	officer: Chief Business Officer	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin	director	11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh	director	7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037